➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Merck
McKinsey
Dow
Colorcon

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BISOPROLOL FUMARATE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Bisoprolol Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00702156 Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease Terminated NHS Greater Glasgow and Clyde Phase 2 2005-03-01 The principal research objectives are to demonstrate cardioselective beta-blockade using bisoprolol is not inferior to placebo with regard to pulmonary function and improves quality of life in patients with heart failure and coexistent moderate or severe chronic obstructive pulmonary disease with or without significant reversibility. Patients will be followed up for 4 months during which bisoprolol will be up-titrated to the maximum clinically tolerated dose. Health status will be assessed using a generic and two disease specific questionnaires, and pulmonary function by spirometry, body box plethysmography, and cardiopulmonary exercise testing.
NCT01741623 Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition Completed IPCA Laboratories Ltd. Phase 1 2012-08-01 This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult human subjects.
NCT01744873 Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition Completed IPCA Laboratories Ltd. Phase 1 2012-08-01 This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in normal, healthy, adult human subjects.
NCT03299452 Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor Recruiting Haining Health-Coming Biotech Co., Ltd. Phase 2 2017-01-01 This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS,safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on the accelerated PDX model screening in subjects with advanced malignant tumor.
NCT03779646 Bisoprolol in DMD Early Cardiomyopathy Not yet recruiting Chinese Academy of Medical Sciences Phase 2/Phase 3 2019-01-01 This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.
NCT03779646 Bisoprolol in DMD Early Cardiomyopathy Not yet recruiting National Natural Science Foundation of China Phase 2/Phase 3 2019-01-01 This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.
NCT03779646 Bisoprolol in DMD Early Cardiomyopathy Not yet recruiting Peking Union Medical College Hospital Phase 2/Phase 3 2019-01-01 This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy(DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI) , half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bisoprolol Fumarate

Condition Name

Condition Name for Bisoprolol Fumarate
Intervention Trials
Heart Failure 1
Fed 1
Fasting 1
Duchenne Muscular Dystrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bisoprolol Fumarate
Intervention Trials
Heart Failure 1
Cardiomyopathy, Dilated 1
Cardiomyopathies 1
Neoplasm Metastasis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bisoprolol Fumarate

Trials by Country

Trials by Country for Bisoprolol Fumarate
Location Trials
India 2
United Kingdom 1
Canada 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bisoprolol Fumarate

Clinical Trial Phase

Clinical Trial Phase for Bisoprolol Fumarate
Clinical Trial Phase Trials
Phase 2/Phase 3 1
Phase 2 2
Phase 1 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bisoprolol Fumarate
Clinical Trial Phase Trials
Completed 2
Recruiting 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bisoprolol Fumarate

Sponsor Name

Sponsor Name for Bisoprolol Fumarate
Sponsor Trials
IPCA Laboratories Ltd. 2
NHS Greater Glasgow and Clyde 1
Laval University 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bisoprolol Fumarate
Sponsor Trials
Other 7
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Harvard Business School
Baxter
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.